BMS Archive

Plant · Scientific monograph

Nigella sativa

Black seed / Black cumin

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Inflammatory Pathways, Immunological Research, Glucose & Metabolic Research, Oxidative Stress Research

Research overview

Historical use

Nigella sativa (black seed) has been used medicinally for over 3,000 years across Islamic, Ayurvedic, and Egyptian traditional medicine. The Prophet Muhammad reportedly stated that black seed is 'a cure for every disease except death' (Sahih Al-Bukhari). Seeds were found in the tomb of Tutankhamun. Traditional uses span respiratory conditions, gastrointestinal ailments, diabetes, headache, and skin conditions.

Modern research context

Nigella sativa has a broad evidence base across metabolic, inflammatory, oncological, and infectious disease domains. An umbrella review of herbal medicines for glycaemic control confirms Nigella sativa improves insulin resistance with few reported adverse effects in type 2 diabetes [5]. A 2026 pilot clinical trial combining a Nigella sativa formulation (NP-101) with immune checkpoint inhibitors (nivolumab and ipilimumab) achieved a 41.7% objective response rate in treatment-resistant neuroendocrine cancers [2]. Systematic review of 15 paediatric RCTs found no statistically significant adverse effects [3]. Thymoquinone improves cognitive function in overweight individuals through antioxidant and anti-inflammatory molecular pathways [1].

Adverse effects

Generally well tolerated in short-term clinical trials with no serious adverse effects in paediatric systematic review [3]. GI effects (nausea, bloating) at high doses. Topical oil may cause contact dermatitis. Thymoquinone at very high doses shows nephrotoxicity in animal models — not replicated at therapeutic human doses. Hypoglycaemia risk when combined with antidiabetic agents [5].

Contraindications

Caution with antidiabetic medications (insulin, metformin, sulfonylureas) due to documented additive glucose-lowering effect [5]. Caution with anticoagulants — thymoquinone inhibits platelet aggregation. Caution with immunosuppressants given immune-modulating properties. Avoid in pregnancy — uterotonic effects documented in animal models.

Clinical and phytochemical data

Used part

Seeds (whole, ground, or cold-pressed oil); standardised thymoquinone extracts

Primary active compounds

  • Thymoquinone (30-48% of volatile oil — primary bioactive)

  • Thymohydroquinone and thymol

  • Dithymoquinone (nigellone)

  • Fixed oils (linoleic acid 50-60%, oleic acid)

  • Nigellidine (alkaloid)

  • Alpha-hederin (saponin)

  • Carvacrol and p-cymene (monoterpenes)

Mechanism of action

Thymoquinone exerts neuroprotective effects in obese and overweight individuals through reduction of oxidative stress, suppression of NF-κB-mediated neuroinflammation, and modulation of AMPK and PI3K/Akt signalling pathways [1]. Antidiabetic activity is mediated through alpha-glucosidase inhibition, GLUT4 upregulation, and pancreatic beta-cell protection [4, 5]. Immunomodulatory properties include modulation of Th1/Th2 cytokine balance and NK cell activity, providing the rationale for combination with immune checkpoint inhibitors in cancer [2]. Anti-Helicobacter pylori activity is mediated through disruption of bacterial cell wall integrity and inhibition of urease enzyme [7]. Alpha-hederin demonstrates apoptotic activity through caspase-3 activation.

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Thymoquinone has limited oral bioavailability due to poor aqueous solubility and rapid first-pass metabolism. Nanoparticle and nanoemulsion formulations have been developed to improve bioavailability, including in paediatric dentistry applications [3]. The fixed oil matrix in whole seed preparations may act as a natural lipid delivery vehicle, enhancing thymoquinone absorption.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Thymoquinone distributes to CNS, liver, kidney, and adipose tissue in animal models. CNS penetration is consistent with documented neuroprotective and cognitive effects in obese individuals [1].

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Thymoquinone is primarily metabolised by hepatic CYP450 enzymes; the specific isoforms involved and potential for drug interactions via CYP450 modulation have not been formally characterised in clinical studies.

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Thymoquinone metabolites are excreted via renal and biliary routes in animal models. Elimination half-life in humans has not been established in published pharmacokinetic studies.

Safety and interactions

Drug interactions

Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.

Toxicity

Systematic review of 15 paediatric RCTs found no statistically significant adverse effects at therapeutic doses [3]. The 2026 clinical trial combining Nigella sativa with immunotherapy reported a manageable safety profile [2]. Thymoquinone shows dose-dependent nephrotoxicity in high-dose animal studies, not replicated at human therapeutic doses. Thymoquinone inhibits platelet aggregation and may increase bleeding risk. Standard whole seed doses (1–3 g/day) have demonstrated a favourable adverse effect profile in short-term adult clinical trials; long-term safety data are limited.

Special precautions

Pregnancy

Uterotonic effects documented in animal studies. Avoid during pregnancy, particularly in the first trimester.

Lactation

Thymoquinone excretion into breast milk not characterised in humans. Use with caution.

Hepatic impairment

CYP450-mediated hepatic metabolism expected; impaired clearance in liver disease. No formal dose adjustment data. Use with caution.

Renal impairment

High-dose thymoquinone nephrotoxicity in animal models warrants caution in renal impairment. No formal human studies. Monitor renal function.

Sources and references

  1. [1] - Mostafa MD, El-Komy MA, Amer ME et al., "The alteration of brain function in overweight/obese individuals and the neurological benefit of thymoquinone: uncovering molecular mechanisms", Metabolic Brain Disease, 2026, PMID: 41920373
  2. [2] - Mohamed A, Azmi A, Kocak M et al., "NP-101 in combination with nivolumab and ipilimumab in metastatic extrapulmonary neuroendocrine carcinomas: A pilot study", Endocrine-Related Cancer, 2026, PMID: 42012995
  3. [3] - Abumadini MM, Ahmad S, AlYahya W et al., "Clinical Uses of Nigella Sativa in Pediatrics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", Journal of Pediatric Pharmacology and Therapeutics, 2025, PMID: 41112345
  4. [4] - Kurnia D, Dharsono HDA, Takaya A et al., "Potential of Secondary Metabolite Compounds of Black Cumin Seeds (Nigella sativa L.) as Therapeutic Agents for Chronic Diseases", Drug Design, Development and Therapy, 2025, PMID: 41169705
  5. [5] - Li E, Maunder A, Liu J et al., "The efficacy and safety of herbal medicines for glycaemic control and insulin resistance in individuals with type 2 diabetes: an umbrella review", BMC Complementary Medicine and Therapies, 2025, PMID: 41029669
  6. [6] - Dashti S, Ashouri A, Bahri N, "Herbal compounds in the treatment of polycystic ovary syndrome: an updated systematic review", Journal of Ovarian Research, 2026, PMID: 41761211
  7. [7] - Boyanova LY, Markovska RD, Gergova RT, "Dietary factors in Helicobacter pylori infection control: A review of in vitro and in vivo data, including case-controls", Nutrition and Health, 2026, PMID: 40836822
  8. [8] - Alicea DS, Han M, Islam Z et al., "Systematic review of prophylactic antibacterial agents for radiation-induced oral mucositis in head and neck cancer", Supportive Care in Cancer, 2026, PMID: 41731134

Additional source links

Continue browsing